Christopher J Sweeney Selected Research

LC-1 compound

10/2008	Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer.
12/2007	An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher J Sweeney Research Topics

Disease

104	Prostatic Neoplasms (Prostate Cancer) 10/2022 - 07/2002
70	Neoplasms (Cancer) 01/2022 - 01/2002
22	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2005
8	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 10/2021 - 09/2003
6	Fatigue 10/2022 - 05/2010
6	Carcinogenesis 01/2021 - 01/2002
6	Carcinoma (Carcinomatosis) 12/2014 - 01/2002
5	Disease Progression 10/2022 - 08/2010
5	Adenocarcinoma 10/2018 - 01/2002
4	Inflammation (Inflammations) 01/2021 - 06/2014
3	Hypertension (High Blood Pressure) 10/2020 - 01/2016
3	Febrile Neutropenia 01/2019 - 01/2006
3	Pancreatic Neoplasms (Pancreatic Cancer) 10/2008 - 04/2005
3	Transitional Cell Carcinoma 07/2006 - 01/2002
2	Seminoma 10/2021 - 10/2012
2	Neutropenia 10/2020 - 02/2008
2	Fibrosis (Cirrhosis) 01/2019 - 09/2003
2	Pain (Aches) 10/2018 - 10/2014
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2017 - 08/2015
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017 - 04/2007
2	Testicular Neoplasms (Testicular Cancer) 01/2016 - 09/2003
2	Teratoma (Teratoid Tumor) 01/2016 - 09/2003
2	Leukemia 05/2015 - 12/2007
2	Thrombocytopenia (Thrombopenia) 12/2014 - 02/2006
2	Lung Neoplasms (Lung Cancer) 05/2011 - 11/2007
2	Urinary Bladder Neoplasms (Bladder Cancer) 05/2011 - 04/2008
2	Diarrhea 02/2008 - 02/2007
2	Breast Neoplasms (Breast Cancer) 06/2005 - 03/2002

Drug/Important Bio-Agent (IBA)

33	AndrogensIBA 01/2022 - 07/2004
30	Hormones (Hormone)IBA 10/2022 - 10/2006
25	Docetaxel (Taxotere)FDA Link 01/2022 - 06/2005
16	Prostate-Specific Antigen (Semenogelase)IBA 12/2020 - 12/2010
13	Biomarkers (Surrogate Marker)IBA 01/2022 - 05/2007
11	enzalutamideIBA 10/2022 - 05/2015
10	parthenolideIBA 10/2018 - 08/2004
9	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 01/2002
8	Proteins (Proteins, Gene)FDA Link 11/2017 - 01/2002
7	NF-kappa B (NF-kB)IBA 01/2021 - 03/2002
6	abirateroneIBA 01/2022 - 12/2015
5	Cisplatin (Platino)FDA LinkGeneric 10/2021 - 04/2011
5	Prednisone (Sone)FDA LinkGeneric 01/2021 - 02/2011
5	Abiraterone AcetateIBA 01/2021 - 02/2017
5	Testosterone (Sustanon)FDA Link 01/2021 - 01/2019
4	taxaneIBA 08/2021 - 02/2007
4	Bevacizumab (Avastin)FDA Link 10/2020 - 05/2010
4	Messenger RNA (mRNA)IBA 01/2019 - 02/2016
4	Pharmaceutical PreparationsIBA 01/2018 - 03/2002
3	cabazitaxel FDA Link 01/2022 - 01/2018
3	Etoposide (VP 16)FDA LinkGeneric 10/2021 - 12/2017
3	CytokinesIBA 12/2020 - 06/2014
3	Paclitaxel (Taxol)FDA LinkGeneric 10/2020 - 02/2005
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 07/2015
3	Biological ProductsIBA 04/2019 - 01/2018
3	Formaldehyde (Formol)FDA Link 01/2019 - 01/2002
3	ParaffinIBA 01/2019 - 01/2002
3	PlatinumIBA 01/2011 - 09/2003
3	Pemetrexed (MTA)FDA Link 07/2006 - 01/2006
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2004 - 03/2002
3	DNA (Deoxyribonucleic Acid)IBA 11/2003 - 01/2002
2	Phosphotransferases (Kinase)IBA 01/2022 - 10/2014
2	atezolizumabIBA 01/2022 - 01/2022
2	ChemokinesIBA 01/2021 - 06/2014
2	pertuzumabIBA 01/2021 - 02/2007
2	Interleukin-8 (Interleukin 8)IBA 12/2020 - 06/2014
2	Radium-223IBA 01/2019 - 01/2018
2	GlucocorticoidsIBA 01/2019 - 02/2016
2	Lysine (L-Lysine)FDA Link 01/2018 - 05/2016
2	RNA (Ribonucleic Acid)IBA 02/2017 - 05/2016
2	Tumor Biomarkers (Tumor Markers)IBA 08/2016 - 02/2012
2	Diphosphonates (Bisphosphonates)IBA 02/2016 - 02/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 07/2004
2	cabozantinibIBA 12/2015 - 10/2014
2	Methotrexate (Mexate)FDA LinkGeneric 06/2014 - 01/2006
2	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2011 - 07/2010
2	Gemcitabine FDA Link 04/2011 - 02/2005
2	Sunitinib (Sutent)FDA Link 10/2010 - 01/2009
2	LC-1 compoundIBA 10/2008 - 12/2007
2	CarcinogensIBA 10/2008 - 11/2007
2	Celecoxib (Celebrex)FDA Link 10/2008 - 11/2007
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2008 - 04/2007
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 11/2007 - 08/2003
2	Sulindac (Copal)FDA LinkGeneric 06/2007 - 04/2005
2	SesquiterpenesIBA 10/2006 - 06/2005
2	Transcription Factors (Transcription Factor)IBA 10/2006 - 04/2005
2	LactonesIBA 10/2006 - 06/2005
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2006 - 04/2005
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2022
1	Metformin (Glucophage)FDA LinkGeneric 01/2022

Therapy/Procedure

69	Therapeutics 01/2022 - 07/2002
36	Castration 01/2022 - 07/2004
17	Drug Therapy (Chemotherapy) 01/2022 - 08/2003
13	Prostatectomy (Retropubic Prostatectomy) 01/2022 - 10/2002
11	Radiotherapy 01/2022 - 12/2010
3	Brachytherapy 11/2016 - 12/2010
3	Combination Drug Therapy (Combination Chemotherapy) 01/2011 - 06/2007
3	Cystectomy 04/2008 - 01/2002
2	Neoadjuvant Therapy 04/2008 - 12/2007
2	Lasers (Laser) 11/2003 - 09/2003
1	Immunotherapy 01/2022